Table 2 Population based studies which have evaluated the average attributable and non-reimbursed cost of HO-CDI in US hospitals
From: Environmental approaches to controlling Clostridioides difficile infection in healthcare settings
Population based studies on the cost of HO-CDI | ||||
|---|---|---|---|---|
Author | Study period | Publication date date | Total attributable cost per case (USD) | Non-reimbursed Cost Per case (USD) |
Shorr [122] | 2008–2010 | 2022 | $28,050 | Not evaluated |
Mollard [123] | 2012–2016 | 2019 | $27,122 | Not evaluated |
Sahrmann [124] | 2011–2017 | 2022 |  | $14,257 |
Yu [125] | 2012–2019 | 2022 | $28,762 | $13,476 |